Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Iovance Biotherapeutics, Inc.    IOVA

IOVANCE BIOTHERAPEUTICS, INC.

(IOVA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 14.9 USD
Weaknesses
  • The stock is close to a major daily resistance at USD 26, which should be gotten rid of so as to gain new appreciation potential.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
IOVANCE BIOTHERAPEUTICS, IN..189.15%3 229
-
GUARDANT HEALTH, INC.95.11%6 887
GENSCRIPT BIOTECH CORPORATI..81.33%4 552
INVITAE CORPORATION60.22%1 710
VERACYTE, INC.130.29%1 415
MIRACA HOLDINGS INC.10.65%1 411
CAREDX, INC-16.11%895
SEEGENE INC--.--%595
INNATE PHARMA-24.01%492
Q-LINEA AB (PUBL)-15.70%123
EPIGENOMICS AG-16.92%69
LYSOGENE-1.88%24
More Results
Financials (USD)
Sales 2019 -
EBIT 2019 -196 M
Net income 2019 -187 M
Finance 2019 318 M
Yield 2019 -
P/E ratio 2019 -17,1x
P/E ratio 2020 -15,5x
EV / Sales2019 infx
EV / Sales2020 112x
Capitalization 3 229 M
Upcoming event on IOVANCE BIOTHERAPEUTICS, I
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes